, Volume 35, Issue 3, pp 1023–1030 | Cite as

Fractalkine Upregulates Inflammation through CX3CR1 and the Jak–Stat Pathway in Severe Acute Pancreatitis Rat Model

  • Li-ya Huang
  • Ping Chen
  • Ling-xiao Xu
  • Yu-fen Zhou
  • Yong-ping Zhang
  • Yao-zong YuanEmail author


Based on the function of chemokine fractalkine (FKN), acting as both adhesion and chemoattractant, FKN plays a role in acute inflammatory response. In this study, we investigated the mechanism of FKN mediated upregulation inflammation in severe acute pancreatitis (SAP) rat models. Western blot, reverse transcriptase-polymerase chain reaction, and immunofluorescence demonstrated that FKN and its receptor CX3CR1 were overexpressed in cerulein-stimulated AR42J cells. AG490 and FKN-siRNA inhibited activation of Janus kinase/signal transducers and activators of transcription (Jak/Stat) in cerulein-stimulated AR42J cells. Following exposure AG490 and FKN-siRNA inhibited tumor necrosis factor-alpha expression by enzyme-linked immunosorbent assay and immunohistochemistry in vivo the SAP rat models. These results showed FKN and CX3CR1 were involved inflammatory response in cerulein-stimulated AR42J cells. FKN upregulates inflammation through CX3CR1 and the Jak/Stat pathway in SAP rat models.


chemokine fractalkine CX3CR1 severe acute pancreatitis Jak/Stat 


  1. 1.
    Harrison, D.A., G. D’Amico, and M. Singer. 2007. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. Critical Care Medicine 35: 1703–1708.PubMedCrossRefGoogle Scholar
  2. 2.
    Bazan, J.F., K.B. Bacon, G. Hardiman, et al. 1997. A new class of membrane bound chemokine with a CX3C motif. Nature 385: 640–644.PubMedCrossRefGoogle Scholar
  3. 3.
    Volin, M.V., J.M. Woods, M.A. Amin, M.A. Connors, L.A. Harlow, and A.E. Koch. 2001. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. The American Journal of Pathology 159: 1521–1530.PubMedCrossRefGoogle Scholar
  4. 4.
    Lee, S.J., S. Namkoong, Y.M. Kim, et al. 2006. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNos-dependent signal pathways. American Journal of Physiology-Heart and Circulatory Physiology 291: H2836–H2846.PubMedCrossRefGoogle Scholar
  5. 5.
    Efsen, E., C. Grappone, R.M. DeFranco, et al. 2002. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. Journal of Hepatology 37: 39–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Segerer, S., E. Hughes, K.L. Hudkins, M. Mack, T. Goodpaster, and C.E. Alpers. 2002. Expression of the fractalkine receptor (CX3CR1) in human kidney disease. Kidney International 62: 488–495.PubMedCrossRefGoogle Scholar
  7. 7.
    Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. Cell 76: 253–262.PubMedCrossRefGoogle Scholar
  8. 8.
    Igaz, P., S. Toth, and A. Falus. 2001. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflammation Research 50: 435–441.PubMedCrossRefGoogle Scholar
  9. 9.
    Rawlings, J.S., K.M. Rosler, and D.A. Harrison. 2004. The JAK/STAT signaling pathway. Journal of Cell Science 117: 1281–1283.PubMedCrossRefGoogle Scholar
  10. 10.
    Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782–1788.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen, P., Y. Yuan, S. Wang, L. Zhan, and J. Xu. 2006. Captopril, an angiotensin converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase. The Tohoku Journal of Experimental Medicine 209: 99–101.PubMedCrossRefGoogle Scholar
  12. 12.
    Yu, J.H., K.H. Kim, and H. Kim. 2006. Suppression of IL-1β expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochemical Pharmacology 72: 1555–1562.PubMedCrossRefGoogle Scholar
  13. 13.
    Grewal, H.P., E.L. Mohey, A. Din, L. Gaber, M. Kotb, and A.O. Gaber. 1994. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am. J. Sug 167: 214–218.CrossRefGoogle Scholar
  14. 14.
    Zhang, Xi-Ping, J. Zhang, Mei-Li Ma, et al. 2010. Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary & Pancreatic Diseases International 9: 83–85.Google Scholar
  15. 15.
    Zhang, Q., K. Shimoya, K. Temma, et al. 2004. Expression of fractalkine in the fallopian tube and of CX3CR1 in sperm. Human Reproduction 19: 409–414.PubMedCrossRefGoogle Scholar
  16. 16.
    Ancuta, P., R. Rao, A. Moses, A. Mehle, et al. 2003. Fractalkine preferentially mediates arrest and migration of CD16 monocytes. Journal of Experimental Medicine 197: 1701–1707.PubMedCrossRefGoogle Scholar
  17. 17.
    Fraticelli, P., M. Sironi, G. Bianchi, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. Journal of Clinical Investigation 107: 1173–1181.PubMedCrossRefGoogle Scholar
  18. 18.
    Umehara, H., E.T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai. 2004. Fractalkine in vascular biology: from basic research to clinical disease. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 34–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Haskell, C.A., M.D. Cleary, and I.F. Charo. 2000. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. Journal of Biological Chemistry 275: 34183–34189.PubMedCrossRefGoogle Scholar
  20. 20.
    Garton, K.J., P.J. Gough, C.P. Blobel, et al. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). Journal of Biological Chemistry 276: 37993–38001.PubMedGoogle Scholar
  21. 21.
    Combadiere, C., S. Potteaus, J.L. Gao, et al. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009–1016.PubMedCrossRefGoogle Scholar
  22. 22.
    Eriksson, E.E. 2004. Mechanisms of leukocyte recruitment to atherosclerosclerotic lesions: future prospects. Current Opinion in Lipidology 15: 5911–5918.CrossRefGoogle Scholar
  23. 23.
    Duxbury, M.S., E. Matros, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whanq. 2004. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Annals of Surgery 240(4): 667–674.PubMedGoogle Scholar
  24. 24.
    Filleur, S., A. Courtin, S. Ali, et al. 2003. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research 63(14): 3919–3922.PubMedGoogle Scholar
  25. 25.
    Sioud, M. 2010. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA inference. Methods in Molecular Biology 629: 33–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2(3): 243–247.PubMedCrossRefGoogle Scholar
  27. 27.
    Chetty, C., P. Bhoopathi, P. Joseph, S. Chittivelu, Js Rao, and S. Lakka. 2006. Adenovirus -mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Molecular Cancer Therapeutics 5(9): 2289–2299.PubMedCrossRefGoogle Scholar
  28. 28.
    Kisseleva, T., S. Bhattacharya, J. Braunstein, and C.W. Schindler. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1–24.PubMedCrossRefGoogle Scholar
  29. 29.
    Pelletier, S., F. Duhamel, P. Coulombe, M.R. Popoff, and S. Meloche. 2003. Rho family GTPase are required for activation of Jak/Stat signaling by G protein couple receptors. Molecular and Cellular Biology 23: 1316–1333.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Li-ya Huang
    • 2
  • Ping Chen
    • 1
  • Ling-xiao Xu
    • 1
  • Yu-fen Zhou
    • 1
  • Yong-ping Zhang
    • 1
  • Yao-zong Yuan
    • 1
    Email author
  1. 1.Department of GastroenterologyRuijin Hospital Shanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of GastroenterologyAffiliated Hospital of Ningxia Medical UniversityYinchuanChina

Personalised recommendations